AstraZeneca raises sales guidance on demand for Covid treatment
The Anglo-Swedish pharmaceutical giant said it expects the Evusheld Covid-19 injection to help drive sales of at least 20% for the year.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.AstraZeneca has hiked its revenue forecast for the year after strong demand for its Covid-19 antibody treatment and cancer medication.
The Anglo-Swedish pharmaceutical giant said it expects the Evusheld Covid-19 injection to help drive sales of at least 20% for the year.
It had previously told shareholders it expected sales to grow in the “high teens”.
Chief executive officer Pascal Soriot said: “AstraZeneca had a strong financial first half of 2022, and great pipeline delivery.
“Given the ongoing performance of our underlying business and the contribution of our Covid-19 medicines, we are updating our revenue guidance for 2022.
“This has enabled us to increase our R&D investment in the exciting number of pipeline opportunities that can benefit patients and drive long term sustainable growth for our company.”
The group hailed the success of the Evusheld treatment, which it said is continuing to “demonstrate activity against new variants”.
It also cheered a “strong” period for oncology, which helped deliver 20% growth over the six months to June.
AstraZeneca said total revenues increased by 48% to 22.16 billion dollars (£18.2 billion) over the half-year as it was boosted by broad organic growth and its £28 billion deal to buy US drugmaker Alexion pharmaceuticals.
Nevertheless, shares in the company drifted lower on Friday as it revealed a 53% decline in operating profits to 1.4 billion dollars (£1.15 billion) for the first six months of the year.
The pharmaceutical firm also confirmed that current board executive Michel Demare will take over as the company’s chair from Leif Johansson next year.